Research programme: inherited muscular disorder therapeutics - Retrophin

Drug Profile

Research programme: inherited muscular disorder therapeutics - Retrophin

Alternative Names: RE-001; RE-002; RE-003

Latest Information Update: 28 Nov 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Retrophin
  • Class Recombinant fusion proteins
  • Mechanism of Action Dystrophin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • Research Congenital structural myopathies; Spinal muscular atrophy

Most Recent Events

  • 28 Nov 2014 Active development for Duchenne muscular dystrophy is ongoing in USA
  • 14 Feb 2013 RE 001 is still in preclinical trials for Duchenne muscular dystrophy in USA (Parenteral)
  • 28 May 2012 Early research in Congenital structural myopathies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top